Figure 5
From: EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
FSCN1 expression was associated with the survival of patients with IDC. (A,B) The association of FSCN1 expression with relapse-free survival (RFS) (A), overall survival (OS) (B) of the IDC patients were analyzed. (C,D) The association of FSCN1 expression with relapse-free survival (RFS) (C), overall survival (OS) (D) of the TNBC patients were analyzed. (E,F) Kaplan-Meier curves for relapse-free survival (RFS) (E), overall survival (OS) (F) of low and high expression of FSCN1 mRNA in TNBC subtype of breast cancer. Data was extracted from TCGA. P values were calculated with Log-rank (Mantel-Cox) test.
